---
title: Evolutionary trajectories of small cell lung cancer under therapy
date: '2024-03-14'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38480884/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240314180555&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: The evolutionary processes that underlie the marked sensitivity of small
  cell lung cancer (SCLC) to chemotherapy and rapid relapse are unknown^(1-3). Here
  we determined tumour phylogenies at diagnosis and throughout chemotherapy and immunotherapy
  by multiregion sequencing of 160 tumours from 65 patients. Treatment-naive SCLC
  exhibited clonal homogeneity at distinct tumour sites, whereas first-line platinum-based
  chemotherapy led to a burst in genomic intratumour heterogeneity and spatial ...
disable_comments: true
---
The evolutionary processes that underlie the marked sensitivity of small cell lung cancer (SCLC) to chemotherapy and rapid relapse are unknown^(1-3). Here we determined tumour phylogenies at diagnosis and throughout chemotherapy and immunotherapy by multiregion sequencing of 160 tumours from 65 patients. Treatment-naive SCLC exhibited clonal homogeneity at distinct tumour sites, whereas first-line platinum-based chemotherapy led to a burst in genomic intratumour heterogeneity and spatial ...